Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. 1991

J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
Servicio de Hematología, Hospital Clínico, Salamanca, Spain.

We have studied phenotypic and clinical features in a consecutive series of 45 patients with chronic myelogenous leukaemia (CML) in blast crisis (BC). In addition, in 22 of these patients we have analysed the genotypic characteristics including immunoglobulin, T-cell receptor (TCR) and major breakpoint cluster region (M-bcr) gene organization. The granulomonocytic and megakaryoblastic lineages are the most commonly involved in these BC of CML (33% and 33% of cases, respectively); only 18% of our cases displayed a lymphoid phenotype. Moreover, both morphological and immunophenotypic studies revealed the frequent coexistence of two or three cell populations, especially when the megakaryoblast component is involved. The lymphoid BC displayed the highest incidence of complete remissions although this was not associated with a longer survival. Only minor differences between the different myeloid subgroups were observed. Immunoglobulin heavy chain (IgH) gene rearrangement was found in five of the six lymphoid BC and in one myeloid BC. Only one case showed k light chain gene rearrangement. In all but one myeloid BC the TCR-beta gene was in germline configuration. The TCR-gamma gene was rearranged in all lymphoid and one myeloid BC, while TCR-delta gene rearrangement was detected in 67% and 16% of the lymphoid and myeloid BC, respectively. Most of the lymphoid BC (4/5) had the M-bcr breakpoint in subregion 3, while the myeloid BC had the breakpoint either in subregion 2 or 3. No differences between the different myeloid phenotypic subgroups were observed in relation to breakpoint.

UI MeSH Term Description Entries
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D015321 Gene Rearrangement The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development. DNA Rearrangement,DNA Rearrangements,Gene Rearrangements,Rearrangement, DNA,Rearrangement, Gene,Rearrangements, DNA,Rearrangements, Gene
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation

Related Publications

J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
November 2000, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
June 1990, The Journal of the Association of Physicians of India,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
July 1985, Scandinavian journal of haematology,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
October 1985, British journal of haematology,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
September 1993, Leukemia,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
February 1997, American journal of clinical pathology,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
January 1997, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
August 1987, Cancer genetics and cytogenetics,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
September 1998, Leukemia & lymphoma,
J M Hernández, and R González-Sarmiento, and C Martin, and M González, and I Sánchez, and J Corral, and A Orfao, and M C Cañizo, and J F San Miguel, and A López-Borrasca
February 1981, Scandinavian journal of haematology,
Copied contents to your clipboard!